相关实验视频

Updated: May 16, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

在现实世界的纵向前性研究中,在不同生物治疗后,牛皮患者的皮肤和全身改善

Epipode Ntawuyamara¹, Baoqing Deng², Yanhua Liang³

¹Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, P.R. China.

Scientific reports

|May 3, 2025

概括

这项研究比较了在中国治疗牛皮的五种生物药物,发现ixekizumab和secukinumab在皮肤清除方面最有效. 所有治疗方法都减少了全身炎症,对葡萄糖和胆固醇等代谢因素产生不同的影响.

科学领域:

皮肤病学皮肤病学
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

牛皮的区域和严重程度指数 (PASI) 是衡量牛皮治疗疗效的常见指标.
现有的措施可能无法完全捕捉对生物疗法的全身反应.
了解不同生物制剂的比较疗效和系统效应对于患者护理至关重要.

研究的目的:

在中国的牛皮患者中,评估和比较24周内阿达利穆马布 (ADA),乌斯特基努马布 (USTE),伊克齐祖马布 (IXE),塞库金努马布 (SECU) 和古塞尔库马布 (GUSE) 的临床和系统辅助益处.
通过PASI,身体表面积 (BSA),皮肤病生命质量指数 (DLQI) 和代谢/炎症标志物来评估这些生物制剂的疗效.
确定研究生物药物治疗反应和系统性影响的差异.

主要方法:

对385名中华患者进行了前性随机队列研究,这些患者患有中度至重度的牛皮.
用五种不同的生物药物进行治疗:ADA,USTE,IXE,SECU和GUSE.
在基线,第4周,第12周和第24周使用PASI,BSA,DLQI和代谢/炎症查进行评估.

主要成果:

从基线到第24周的所有治疗中观察到显著的临床改善 (p < .001).
伊克西祖马布 (IXE) 和塞库金乌马布 (SECU) 显示出更高的PASI 100率 (分别在第24周为87.27%和89.92%).
古塞尔库马布 (GUSE) 显示出更快的全身改善和对脂质特征的影响,而SECU和ADA则分别影响了葡萄糖和尿酸水平.

结论:

所有研究的生物制剂都有效地实现显著的皮肤清除和减少牛皮患者的全身炎症.
IXE和SECU在实现完全皮肤清除方面非常有效 (PASI 100).
生物体对代谢参数表现出不同的影响,这表明个性化治疗方法可能是有益的.

关键词:

生物治疗方法生物治疗方法完整的皮肤清除.有效性有效性.炎症炎症是一种炎症.代谢过程中的代谢.牛皮是一种病.

更多相关视频

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...